There is an urgency to treat Persistent Cardiovascular Risk (P-CVR) as it remains high despite statin-based standard-of-care therapy in patients with elevated triglycerides. In this program, we will review data from a practice changing trial that provides a new therapeutic option to elevate the current standard of care.Presenter: Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE EndocrinologistMedical Director & Principal InvestigatorMetabolic Institute of AmericaTarzana, CA